These emerging treatments , including Semaglutide , belong to a class of drugs called GLP-1 receptor agonists . Primarily approved for treating high blood sugar, they operate by helping the organism to release adequate the hormone insulin and curbing high blood sugar levels. Additionally , their potential to support slimming has led to substantial